Last updated: July 17, 2026

Application No. 18/343,968

NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF

Final Rejection

Filed

Jun 29, 2023

Priority

Jan 31, 2017 — provisional 62/452,963 +7 more

Examiner

DEVI, SARVAMANGALA

Art Unit

1645

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Pfizer Inc.

OA Round

4 (Final)

Interview Optional

— +55.0% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 65% grant rate with +55.0% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 868 resolved cases, 2023–2026

Examiner Intelligence

DEVI, SARVAMANGALA View full profile →

Grants 65% — above average

Career Allowance Rate

568 granted / 868 resolved

+5.4% vs TC avg

Strong +55% interview lift

Without

With

+55.0%

Interview Lift

resolved cases with interview

Typical timeline

3y 4m

Avg Prosecution

44 currently pending

Career history

925

Total Applications

across all art units

Statute-Specific Performance

§101

0.6%

-39.4% vs TC avg

§103

28.5%

-11.5% vs TC avg

§102

25.1%

-14.9% vs TC avg

§112

25.5%

-14.5% vs TC avg

Black line = Tech Center average estimate • Based on career data from 868 resolved cases

Prosecution Timeline

Show 3 earlier events

May 29, 2025

Examiner Interview Summary

May 29, 2025

Examiner Interview (Telephonic)

Jul 14, 2025

Final Rejection mailed

Oct 14, 2025

Request for Continued Examination

Oct 15, 2025

Response after Non-Final Action

Nov 19, 2025

Non-Final Rejection mailed

Mar 19, 2026

Response Filed

Jun 24, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/757,972

Patent 12667611

NEW USE OF BCG IMMUNOGENIC FORMULATION EXPRESSING A RESPIRATORY SYNCITIAL VIRUS PROTEIN AGAINST hMPV

4y 0m to grant Granted Jun 30, 2026

18/425,772

Patent 12661411

MONOCLONAL ANTIBODY AND VACCINE TARGETING FILAMENTOUS BACTERIOPHAGE

2y 4m to grant Granted Jun 23, 2026

18/570,332

Patent 12636322

BACTERIAL STRAIN WITH HIGH CELLULOLYTIC ACTIVITY

2y 5m to grant Granted May 26, 2026

18/768,336

Patent 12637495

DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS

1y 10m to grant Granted May 26, 2026

18/386,593

Patent 12629409

VACCINE

2y 6m to grant Granted May 19, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6

Expected OA Rounds

65%

Grant Probability

99%

With Interview (+55.0%)

3y 4m (~3m remaining)

Median Time to Grant

High

PTA Risk

Based on 868 resolved cases by this examiner. Grant probability derived from career allowance rate.